NCT06707155Completed
Digital Tracking With Auto Data Reporting
Study on the Use of Digital Platforms for the Control of Insulin Treatment in Patients With Type 1 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 5 Jun 2025
Brief summary (registry, in English)
Type 1 diabetes mellitus is a chronic pathology and represents a constant challenge for children and adolescents with diabetes and their families. The objective of the treatment of DM1 in pediatric age is to achieve and maintain an optimal glycemic control in order to avoid or delay chronic micro- and macrovascular complications related to the disease. However, currently, despite technological advances and the development of new insulin formulations, the majority of patients are unable to achieve glycemic goals. In this context, the use of digital tools/platforms that allow remote monitoring of patients and that facilitate telemedicine have shown potential to improve treatment adherence and facilitate continued therapeutic education, improving clinical results with savings in time and associated costs.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25 (actual)
- First submitted
- 19 Nov 2024
- Start date
- 22 Jul 2024
- Primary completion date
- 4 Jan 2025
- Lead sponsor
- Persei Vivarium
- Diseases
- Type 1 diabetes
- NCT number
- NCT06707155
What you commit to
- Study type: Observational
- Participants enrolled: 25
- From 22 Jul 2024 to the primary completion date, 4 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who, in the opinion of the investigator will not be able to commit to carrying out the follow-ups or do not have adequate technological skills
Who the study is looking for
- Patients with type 1 diabetes mellitus
- Patients treated with subcutaneous insulin in multiple daily doses or patients treated with subcutaneous insulin in continuous subcutaneous infusion systems
- Patients using a glucose monitoring system
- Patients who are able to complete the study questionnaires
- Patients who are able to handle the application on a smart mobile phone.
- Informed consent is obtained from the patient.
Age in the registry: 3 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Infantil Universitario Nino Jesus Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.